Experts Urge Stopping Melanoma Trial Because of Failure and Harm

New results from a phase 3 trial may shut the door on the addition of PD–1 or PD–ligand 1 inhibitors to the combination of BRAF and MEK inhibitors for the treatment of BRAF V600–mutated melanoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/974244?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors